AcquisitionsJul 29, 2026, 04:13 PM
MIMEDX to Acquire Sanara MedTech for $350M; Q2 Net Loss $14.8M
AI Summary
MIMEDX Group, Inc. announced a definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in a cash and stock transaction, expected to close in 2026. This acquisition will be financed by a new $300 million senior secured term loan from Hayfin Capital Management LLP. For the second quarter of 2026, MIMEDX reported a net loss of $14.8 million, a significant decrease from a net income of $9.6 million in the prior year period. Net sales fell 34.7% to $64.4 million, primarily due to a 61.1% decline in Wound sales, though Surgical sales saw a 15.1% increase.
Key Highlights
- MIMEDX to acquire Sanara MedTech for approximately $350 million in cash and stock.
- Acquisition to be financed by a 6-year, $300 million senior secured term loan from Hayfin.
- Q2 2026 net loss was $14.8 million, compared to net income of $9.6 million in Q2 2025.
- Q2 2026 net sales decreased 34.7% to $64.4 million from $98.6 million year-over-year.
- Wound sales declined 61.1% to $25.1 million in Q2 2026.
- Surgical sales grew 15.1% to $39.3 million in Q2 2026.
- Cash and cash equivalents stood at $135.8 million as of June 30, 2026.
- Company plans to prepay the remaining $17.3 million Citizens Term Loan balance.
Price Impact
More from MDXG